Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 28;9(10):3136.
doi: 10.3390/jcm9103136.

Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19

Affiliations

Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19

Enrique Rodilla et al. J Clin Med. .

Abstract

It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.

Keywords: COVID-19; all-cause mortality; angiotensin II receptor blockers (ARBs); angiotensin-converting enzyme inhibitors (ACEIs); hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient inclusion flow chart.
Figure 2
Figure 2
All-cause Mortality according to Hypertension status and previous antihypertensive treatment. * p < 0.0001; + p < 0.001; ⯀ p < 0.01.
Figure 3
Figure 3
Kaplan–Meier curves in patients with/without hypertension according to previous antihypertensive treatment. Log rank p < 0.001.

References

    1. Johns Hopkins University Website. [(accessed on 14 August 2020)]; Available online: https://coronavirus.jhu.edu/map.html.
    1. Guan W.J., Ni Z.Y., Hu Y., Liang C., Ou J., He L., Liu H., Shan C., Lei D.S.C., Hui B., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Grasselli G., Zangrillo A., Zanella A., Massimo A., Luca C., Antonio C., Danilo C., Antonio C., Giuseppe F., Roberto F., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region. JAMA. 2020;323:1574–1581. doi: 10.1001/jama.2020.5394. - DOI - PMC - PubMed
    1. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization; Geneva, Switzerland: 2011.
    1. Liang W., Liang H., Ou L., Chen B., Chen A., Li C., Li Y., Guan W., Sang L., Lu J., et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Int. Med. 2020:e202033. doi: 10.1001/jamainternmed.2020.2033. - DOI - PMC - PubMed